Radium-223 might benefit patients with hormone-refractory prostate cancer
This article has no abstract so we have provided the first paragraph of the full text.
The high risk of bone involvement in cases of hormone-refractory prostate cancer has previously been treated with bisphosphonates (which reduce the risk of skeletal events but do not extend survival) or beta-emitting radioisotopes, which improve pain but have myelotoxic effects. Nilsson and colleagues conducted a small, randomized, placebo-controlled, phase II trial of the alpha-emitter radium-223 (223Ra) for the treatment of these patients. A phase I trial in patients with metastatic bone disease had shown preferential uptake of 223RA in skeletal metastases and that the treatment was well tolerated.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.